Review paper
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Volume: 97, Issue: 6, Pages: 683 - 694
Published: Apr 24, 2013
Abstract
Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies. In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are associated with adverse prognosis. Therefore, the FLT3 receptor is an appealing...
Paper Details
Title
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Published Date
Apr 24, 2013
Volume
97
Issue
6
Pages
683 - 694
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History